Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.45 |
| ▸ | CCR8 | P51685 | 3/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102824 | 0.89 | L3MBTL1 (0.43) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1102737 | 0.89 | KDM4E (0.52) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL1103081 | 0.87 | L3MBTL1 (0.42) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL1103120 | 0.87 | L3MBTL1 (0.42) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL1103109 | 0.87 | L3MBTL1 (0.42) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL1103115 | 0.87 | L3MBTL1 (0.42) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL12655787 | 0.87 | KDM4E (0.54) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL1102949 | 0.85 | L3MBTL1 (0.41) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL1103097 | 0.85 | L3MBTL1 (0.41) | KDM4ELMNANPC1TOP1ALDH1A1 | |
| SCHEMBL1102789 | 0.85 | L3MBTL1 (0.41) | KDM4ELMNANPC1TOP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | CYP2A6 1911/4885KDM4E 3367/4885LMNA 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.